EBRD offers massive expansion of motorways in Bosnia and Herzegovina

Region:

Europe

The European Bank for Reconstruction and Development (EBRD) is offering a massive increase in its support for the development and modernisation of the road infrastructure in Bosnia and Herzegovina.

A Memorandum of Understanding signed between the EBRD and the Ministers of Transport and Communications of the Federation of Bosnia and Herzegovina and Republika Srpska, outlines an investment programme of over €700 million for the period 2018-2020.

View source

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating...

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the...

Life sciences: DFIs test a new frontier in health PPP

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even...

Must See

Green Sky SAF: An Egypt first with lending precedents

Perspective

04 June 2026

Green Sky SAF: An Egypt first with lending precedents

A landmark sustainable aviation fuel project in Egypt shows that commercial banks and local equity can get behind emerging transportation fuels. But shared experience on an earlier SAF financing helped assure a painless close.

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating deals, and learning to measure impact

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the development finance industry.

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even vaccine sovereignty is hard to bank without public risk-sharing, demand visibility and unusually credible developers.